ABZYME THERAPEUTICS LLC

Pottstown, PA · Biotech · Private

Engineered uricase enzyme with immune-escape mutations and glycan shield for hyperuricemia treatment

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · abzymetx.com

Sector: Biotech
Headquarters: Pottstown, PA
Total capital: $11.4M

Federal grants: $9.6M; 25 awards · 2014–2025; Rank in peer group#271 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $1.8M; 5 awards · Defense, Health and Human S; Rank in Biotech#143 of 4373
Granted patents: 3; 5 pending · first 2020; Rank in peer group#109 of 514

Capital timeline

Latest events

Mar 2025Federal grantHealth and Human S · Phase II · Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases$826K
Feb 2024Federal grantHealth and Human S · Phase II · Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases$832K
May 2023Federal grantHealth and Human S · Phase I · Novel immune-escape uricase for treatment of hyperuricemia$300K
May 2023Federal grantHealth and Human S · Phase I · Novel immune-escape uricase for treatment of hyperuricemia$300K
Sep 2021Federal grantHealth and Human S · Phase I · Brain-cell penetrating antibodies for treatment of progressive multiple sclerosis$399K
Sep 2021Federal grantHealth and Human S · Phase I · Brain-cell penetrating antibodies for treatment of progressive multiple sclerosis$399K
Sep 2019Federal grantHealth and Human S · Phase I · Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases$300K

Show 23 earlier federal awards

Aug 2019Federal grantHealth and Human S · Phase I · Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases$300K
Aug 2019Federal grantHealth and Human S · Phase I · Pemphigus-specific T cell engagers for pemphigus targeted immunotherapy$280K
May 2019Federal contractHealth and Human S · The Objective Of This Contract Is To Develop Camelid Vhhs That Are Capable Of Significantly (at Least 5-FOLD Improvement)enhancing GP120 Expression In Mammalian Cells And Applicable For Rapid And Scalable GP120 Protein Purification.$300K
Sep 2018Federal contractHealth and Human S · Igf::ot::igf Monoclonal Antibodies To Rna-modifications (moonshot)$300K
Aug 2018Federal grantHealth and Human S · Phase II · High throughput camelid antibody screening as a drug discovery platform$170K
Nov 2017Federal contractDefense · Igf::ot::igf R&d Exempt$1.0M
Sep 2017Federal grantHealth and Human S · Phase I · Modular antibody engineering to overcome the blood brain barrier$237K
Sep 2017Federal grantHealth and Human S · Phase I · Development Of Arginine Linkage Specific Antibodies$225K
Sep 2017Federal grantHealth and Human S · Phase I · Development Of Arginine Linkage-Specific Antibodies$225K
Aug 2017Federal grantHealth and Human S · Phase II · High throughput camelid antibody screening as a drug discovery platform$750K
Sep 2016Federal grantHealth and Human S · Phase II · High throughput camelid antibody screening as a drug discovery platform$1.7M
Aug 2016Federal grantHealth and Human S · Phase II · High throughput camelid antibody screening as a drug discovery platform$750K
Jun 2016Federal grantHealth and Human S · Phase I · Novel approach for rapid generation of human antibodies to RNA-modifications$225K
Jun 2016Federal contractDefense · Igf::ot::igf$150K
Mar 2016Federal grantHealth and Human S · Phase I · Hybridoma-free multiplex approach for accelerating mouse monoclonal antibody generation$40K
Dec 2015Federal contractDefense · Igf::ot::igf$100K
Jun 2015Federal grantHealth and Human S · Phase I · High throughput approach for generating human monoclonal antibodies$225K
Jun 2015Federal grantAgriculture · An Instant Estrogen Sensor For Poultry Gender Sorting Automation$100K
Jun 2015Federal grantHealth and Human S · Phase I · Hybridoma-free multiplex approach for accelerating mouse monoclonal antibody generation$265K
Apr 2015Federal grantHealth and Human S · Phase I · Hybridoma free multiplex approach for accelerating mouse monoclonal antibody generation$225K
Feb 2015Federal grantHealth and Human S · Phase I · Nanobodies for topical delivery to inhibit abnormal choroidal angiogenesis$225K
Feb 2015Federal grantHealth and Human S · Phase I · Nanobodies for topical delivery to inhibit abnormal choroidal angiogenesis$225K
Jun 2014Federal grantAgriculture · Low Cost Approach For Production Of Sweet Proteins As Sugar Substitutes$100K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grantsBelow median
Granted patents#109 · top 21%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 3 granted of 8

Oct 15, 2024GrantedANTIBODIES BINDING TO HUMAN CD3 AT ACIDIC pHUSPTOUS 12,116,411
Apr 6, 2021GrantedMethods For Generating Bispecific Functional AgentsUSPTOUS 10,968,444
Jul 7, 2020GrantedTriple-mode System For Antibody Maturation, Surface Display And SecretionUSPTOUS 10,704,040

Show all 8 patent records

ANTIBODIES BINDING TO HUMAN CD3 AT ACIDIC pHOct 15, 2024 · US 12,116,411Granted
Methods For Generating Bispecific Functional AgentsApr 6, 2021 · US 10,968,444Granted
Triple-mode System For Antibody Maturation, Surface Display And SecretionJul 7, 2020 · US 10,704,040Granted
Composition And Method For Diversifying Polypeptide LibrariesJun 29, 2017 · Application 15380105Pending
Composition and method for Diversifying polypeptide librariesApplication 62387511Pending
ANTIBODIES BINDING TO HUMAN CD3 AT ACIDIC pHApplication 63109005Pending
Methods For Generating Bispecific Functional AgentsApplication 62530960Pending
Triple-mode System For Antibody Maturation, Surface Display And SecretionApplication 62509360Pending

IDBIOLOGICS INCSimilar federal contract value in Biotech · $1.9M in contracts
PHOTOLITEC LLCSimilar federal contract value in Biotech · $1.9M in contracts
MAXCYTE, INC.Similar federal contract value in Biotech · $1.9M in contracts
INTEGRATED RESEARCH ASSOCIATES, LLCSimilar federal contract value in Biotech · $1.8M in contracts
LUCERNA INCSimilar federal contract value in Biotech · $1.8M in contracts
Blaze Bioscience, Inc.Similar federal contract value in Biotech · $1.7M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.